治疗性低温与正常体温在成人创伤性脑损伤中的比较:功能结局、死亡率与不良事件的系统评价与Meta分析
该研究系统检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials,纳入32项随机临床试验、共3909例创伤性脑损伤患者,比较治疗性低温与正常体温。汇总分析显示治疗性低温对死亡率和功能结局有显著获益(死亡率RR 0.81,95% CI 0.68-0.96,I²=41%;功能结局RR 0.77,95% CI 0.67-0.88,I²=68%),但基于偏倚风险亚组分析显示仅高偏倚风险研究维持该获益。治疗性低温组肺炎(RR 1.24,95% CI 1.10-1.40,I²=32%)、凝血异常(RR 1.63,95% CI 1.09-2.44,I²=55%)和心律失常(RR 1.78,95% CI 1.05-3.01,I²=21%)发生率升高,但在低偏倚风险组中这些并发症无差异。作者结论为治疗性低温在死亡率和功能结局方面未显示优于正常体温。
要点
- 汇总32项随机临床试验共3909例创伤性脑损伤患者,治疗性低温组死亡率RR 0.81(95% CI 0.68-0.96,I²=41%)、功能结局RR 0.77(95% CI 0.67-0.88,I²=68%),但仅高偏倚风险研究维持该获益。
- 按降温方式分层,体表降温组(RR 0.68,95% CI 0.59-0.79,I²=35%)和头部降温组(RR 0.44,95% CI 0.29-0.67,I²=0%)不良功能结局减少,全身静脉或胃内降温组无差异。
- 死亡率降低仅见于体表降温组(RR 0.63,95% CI 0.53-0.75,I²=0%),但该组研究多为高偏倚风险。
- 治疗性低温组肺炎(RR 1.24,95% CI 1.10-1.40,I²=32%)、凝血异常(RR 1.63,95% CI 1.09-2.44,I²=55%)和心律失常(RR 1.78,95% CI 1.05-3.01,I²=21%)发生率升高,低偏倚风险组中这些并发症无差异。
- 证据质量:死亡率和功能结局为中等,肺炎为中等,凝血异常和心律失常为低。
适用人群与场景
- 成人创伤性脑损伤患者,来自32项随机临床试验,共3909例。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入32项随机临床试验,共3909例创伤性脑损伤患者,比较治疗性低温与正常体温。
- 主要终点:治疗性低温组死亡率RR 0.81(95% CI 0.68-0.96,I²=41%),功能结局RR 0.77(95% CI 0.67-0.88,I²=68%)。
- 偏倚风险亚组分析:仅高偏倚风险研究维持死亡率和功能结局获益。
- 降温方式亚组:体表降温组不良功能结局RR 0.68(95% CI 0.59-0.79,I²=35%),头部降温组RR 0.44(95% CI 0.29-0.67,I²=0%),全身静脉或胃内降温组无差异;死亡率降低仅见于体表降温组(RR 0.63,95% CI 0.53-0.75,I²=0%),但该组多为高偏倚风险研究。
- 不良事件:肺炎RR 1.24(95% CI 1.10-1.40,I²=32%),凝血异常RR 1.63(95% CI 1.09-2.44,I²=55%),心律失常RR 1.78(95% CI 1.05-3.01,I²=21%);低偏倚风险组中这些并发症无差异。
- 证据质量:死亡率和功能结局为中等,肺炎为中等,凝血异常和心律失常为低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入32项随机临床试验。
- 证据质量:死亡率和功能结局为中等,肺炎为中等;凝血异常和心律失常为低。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,与正常体温相比,治疗性低温在创伤性脑损伤患者的死亡率和功能结局方面未显示获益。
- 亚组分析提示体表降温和头部降温与不良功能结局减少相关,但死亡率降低仅见于体表降温组且该组多为高偏倚风险研究,低偏倚风险组中并发症无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The main focus of traumatic brain injury (TBI) management is prevention of secondary injury. Therapeutic hypothermia (TH), the induction of a targeted low core body temperature, has been explored as a potential neuroprotectant in TBI. The aim of this article is to synthesize the available clinical data comparing the use of TH with the use of normothermia in TBI.
METHODS: A systematic search was conducted through MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for randomized clinical trials including one or more outcome of interest associated with TH use in TBI. Independent reviewers evaluated quality of the studies and extracted data on patients with TBI undergoing TH treatment compared with those undergoing normothermia treatment. Pooled estimates, confidence intervals (CIs), and risk ratios (RRs) or odds ratios were calculated for all outcomes.
RESULTS: A total of 3,909 patients from 32 studies were eligible for analysis. Pooled analysis revealed a significant benefit of TH on mortality and functional outcome (RR 0.81, 95% CI 0.68-0.96, I2 = 41%; and RR 0.77; 95% CI 0.67-0.88, I2 = 68%, respectively). However, subgroup analysis based on risk of bias showed that only studies with a high risk of bias maintained this benefit. When divided by cooling method, reduced poor functional outcome was seen in the systemic surface cooling and cranial cooling groups (RR 0.68, 95% CI 0.59-0.79, I2 = 35%; and RR 0.44, 95% CI 0.29-0.67, I2 = 0%), and no difference was seen for the systemic intravenous or gastric cooling group. Reduced mortality was only seen in the systemic surface cooling group (RR 0.63, 95% CI 0.53-0.75, I2 = 0%,); however, this group had mostly high risk of bias studies. TH had an increased rate of pneumonia (RR 1.24, 95% CI 1.10-1.40, I2 = 32%), coagulation abnormalities (RR 1.63, 95% CI 1.09-2.44, I2 = 55%), and cardiac arrhythmias (RR 1.78, 95% CI 1.05-3.01, I2 = 21%). Once separated by low and high risk of bias, we saw no difference in these complications in the groups with low risk of bias. Overall quality of the evidence was moderate for mortality, functional outcome, and pneumonia and was low for coagulation abnormalities and cardiac arrhythmias.
CONCLUSIONS: With the addition of several recent randomized clinical trials and a thorough quality assessment, we have provided an updated systematic review and meta-analysis that concludes that TH does not show any benefit over normothermia in terms of mortality and functional outcome.
参考来源
- Martyniuk A, Hart S, Lannon M, et al. Therapeutic Hypothermia Compared with Normothermia in Adults with Traumatic Brain Injury; Functional Outcome, Mortality, and Adverse Effects: A Systematic Review and Meta-Analysis. Neurocrit Care. 2024. PMID: 38664327. doi:10.1007/s12028-024-01985-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。